Abstract
This study aimed to investigate the effect of a established cancer drug such as tamoxifen (TMX) and its encapsulation into a matrix of copolymer of ethyl acrylate, methyl methacrylate and a low content of methacrylic acid ester with quaternary ammonium groups (EUDRAGIT® RL 100) associated with a fluorescence probe such as fluorescein. TMX is used in breast cancer therapy with some side effects such as stroke, and endometrial cancer. The new drug delivery system (TMX‐NP) was designed to protect the drug from environmental and to promote a sustained drug delivery profile of the drug and also be tracked by the emission of fluorescence probe. The size and entrapment efficiency were evaluated at different preparation protocols. TMX showed a maximum entrapment efficient of 23% in the proportion of 1,5g of polymer and association to the fluorescence probe using a emulsion method. The size measurements were compared with the empty nanoparticles and showed values of TMX‐NP = 166.4± 32 nm, and empty NP = 273± 50 nm. The zeta potential of particles was +65 and +38 mV for TMX‐NP and empty NP respectively. The new drug delivery system posses some features parameter that allow it to be tested in biological samples such as cancer cells. Supported by FAPDF, CAPES, CNPq, FINATEC and DPP‐UnB.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call